Market Analysis and Insights: Global Oncolytic Virus Immunotherapy Market
Oncology Immunotherapy exploits virus's ability to replicate selectively and kill tumor tissue while at the same time regulate the specific immune response of a patient The first oncolytic virus to demonstrate a clinical benefit in patients with melanoma is genetically modified herpes simplex virus type I i.e. Talimogene laherparepvec (T-VEC).
The global Oncolytic Virus Immunotherapy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
North America is leading in the oncolytic virus immunotherapy market globally, according to Skin Cancer Foundation Statistics, Globally 132,000 melanoma skin cancers occur each year. One in every three cancers diagnosed is a skin cancer, and one in every five Americans will develop skin cancer in their lifetime. North America has well-developed healthcare infrastructure with massive investment in research and development of oncolytic virus immunotherapy.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncolytic Virus Immunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncolytic Virus Immunotherapy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncolytic Virus Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncolytic Virus Immunotherapy market.
Global Oncolytic Virus Immunotherapy Scope and Market Size
Oncolytic Virus Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Oncolytic Virus Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Engineering Oncolytic Viruses
Wild-Type Oncolytic Viruses
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Merck
Amgen
TILT Biotherapeutics
Oncorus
Sorrento Therapeutics
Shanghai Sunway Biotech